(Q36583732)

15 August 2017

1 reference

title

Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites (English)

1 reference

15 August 2017

1 reference

1 reference

Tushar K Vyas

1

1 reference

15 August 2017

Lipa Shah

series ordinal

2

1 reference

15 August 2017

Mansoor M Amiji

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

Expert Opinion on Drug Delivery

15 August 2017

published in

1 reference

15 August 2017

volume

3

1 reference

15 August 2017

issue

5

1 reference

15 August 2017

page(s)

613-628

1 reference

Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Clinical utility of current NNRTIs and perspectives of new agents in this class under development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Current trends of HIV disease of the mouth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Causes of the decline in AIDS deaths, United States, 1995-2002: prevention, treatment or both?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Screening for HIV: A Review of the Evidence for the U.S. Preventive Services Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Early penetration of the blood-brain-barrier by HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Antiretroviral compounds: mechanisms underlying failure of HAART to eradicate HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

The science of megestrol acetate delivery: potential to improve outcomes in cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Engineering of nanoemulsions for drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Nanomedicines for overcoming biological barriers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Nanomedicine: current status and future prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

New technologies for drug delivery across the blood brain barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Targeting intracellular targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Basics of the virology of HIV-1 and its replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Clinical implications of CNS penetration of antiretroviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Antiretroviral therapy regimens for neuro-AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Antiretroviral treatment of central nervous system HIV-1 infection: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

HIV-1 assembly and maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

The ins and outs of HIV replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Inhibitors of virus replication: recent developments and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Anti-HIV drug development--an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Morphometry, histopathology, and tomography of cerebral atrophy in the acquired immunodeficiency syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Magnetic resonance imaging morphometric analysis of cerebral volume loss in human immunodeficiency virus infection. The HNRC Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

HIV encephalitis, proviral load and dementia in drug users and homosexuals with AIDS. Effect of neocortical involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Intranasal drug delivery for brain targeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Didanosine: an updated review of its use in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

A single-dose study to assess the penetration of stavudine into human cerebrospinal fluid in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS Clinical Trial Group and Neurological AIDS Research Consortium study team

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Indinavir in cerebrospinal fluid of HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Hepatotoxicity of antiretroviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Antiretroviral therapy and the kidney: balancing benefit and risk in patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Prospects for the resistance to HIV protease inhibitors: current drug design approaches and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Prodrugs of HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

The impact of efflux transporters in the brain on the development of drugs for CNS disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Increased drug delivery to the brain by P-glycoprotein inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Effects of a P-glycoprotein inhibitor on brain and plasma concentrations of anti-human immunodeficiency virus drugs administered in combination in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Detection of proviruses and viral RNA in the early stages of feline immunodeficiency virus infection in cats: a possible model of the early stage of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Ability of CD8(+) T cell anti-feline immunodeficiency virus activity correlated with peripheral CD4(+) T cell counts and plasma viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Liposomes in the treatment of infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Liposome-mediated delivery of antiviral agents to human immunodeficiency virus-infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Effective drug delivery by PEGylated drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

The use of cell-penetrating peptides for drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Property-based design: optimization of drug absorption and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Strategies in the Design of Prodrugs of Anti-HIV Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Ultrasound-induced mild hyperthermia as a novel approach to increase drug uptake in brain microvessel endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Drug targeting. Breaking down barriers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Development of microspheres for neurological disorders: from basics to clinical applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Distribution of intracerebral ventricularly administered neurotrophins in rat brain and its correlation with trk receptor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

21 January 2018

Phospholipid nanosomes

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Designing of 'intelligent' liposomes for efficient delivery of drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Physical chemical considerations of lipid-based oral drug delivery--solid lipid nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Solid lipid nanoparticles as drug delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Drug delivery to the brain--realization by novel drug carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Therapeutic applications of lipid-coated microbubbles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 2. In vivo distribution and tumor localization studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Lipid-core micelles for targeted drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Macrophage specific drug delivery in experimental leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Lipid–Drug Association Enhanced HIV-1 Protease Inhibitor Indinavir Localization in Lymphoid Tissues and Viral Load Reduction: A Proof of Concept Study in HIV-2287-Infected Macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Feline immunodeficiency virus infection of macrophages: in vitro and in vivo inhibition by dideoxycytidine-5'-triphosphate-loaded erythrocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Targeting of 3'-azido 3'-deoxythymidine (AZT)-loaded poly(isohexylcyanoacrylate) nanospheres to the gastrointestinal mucosa and associated lymphoid tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.613

21 January 2018

Identifiers

DOI

10.1517/17425247.3.5.613

1 reference

15 August 2017

1 reference